Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Ryazanenergosbyt reported for 6 months of 2024 by RAS

7/29/24 RZSB

INARCTICA reported for 6 months of 2024 by RAS

7/29/24 AQUA

Himprom reported for 6 months of 2024 by RAS

7/29/24 HIMCP

Nornickel's production performance continued to decline

7/29/24 GMKN

Lenta reported an increase in performance

7/29/24 LENT

Lenta reported for 6 months of 2024 by IFRS

7/29/24 LENT

Rosseti South reported for 6 months of 2024 by RAS

7/29/24 MRKY

Rosseti Urals reported for 6 months of 2024 by RAS

7/29/24 MRKU

Artgen reported for 6 months of 2024 by RAS

7/29/24 ABIO

Seligdar completed field work at the Chulkovskaya area

7/29/24 SELG